One of the studied sigma-2 antagonists, named ElaytaTM (or CT1812), has entered a phase 2 clinical trial with 540 patients with early Alzheimer’s disease (Grundman et al., 2019) (ClinicalTrials.gov identifier NCT03522129). The gene discussed is AP2S1; the disease is Alzheimer disease.